<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868877</url>
  </required_header>
  <id_info>
    <org_study_id>MCLA-129-CL01</org_study_id>
    <nct_id>NCT04868877</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors</brief_title>
  <official_title>Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merus N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merus N.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1/2 open-label multicenter study will be performed with an initial dose escalation&#xD;
      part to determine the MTD and/or the RP2D of MCLA-129 as monotherapy in patients with NSCLC,&#xD;
      or HNSCC or other solid tumors and who have progressed after receiving prior therapy for&#xD;
      advanced/metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent MCLA-129 in patients with NSCLC, HNSCC or other solid tumors, with disease progression after prior therapy for advanced/metastatic disease.</measure>
    <time_frame>First 28 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary antitumor activity in terms of best overall response (BOR)</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary antitumor activity in terms of overall response rate (ORR)</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary antitumor activity in terms of disease control rate (DCR)</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary antitumor activity in terms of duration of response (DoR).</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression-free survival (PFS)</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate overall survival (OS).</measure>
    <time_frame>Every 8 weeks until study ends, approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at 0 hours [C0h]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time zero to time t [AUC0-t]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve [AUC0-∞]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration [tmax]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life [t1/2]</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in cytokines (TNFα) in serum blood following administration of MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in cytokines (IFNγ) in serum blood following administration of MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in cytokines (IL-1β) in serum blood following administration of MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in cytokines (IL-2) in serum blood following administration of MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in cytokines (IL-6) in serum blood following administration of MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies in serum blood against MCLA-129</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum titers of anti-drug (MCLA-129) antibodies in serum blood</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>MCLA-129</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCLA-129</intervention_name>
    <description>In the dose escalation phase 1 part, MCLA-129 will be administered every two weeks with increasing doses to patients with NSCLC or patients with HNSCC, or other solid tumors, who in all cases, have progressed after receiving prior therapy for advanced/metastatic disease. In Part 2, patients with NSCLC and other advanced solid tumors will be dosed with MCLA-129 every two weeks at the RP2D.</description>
    <arm_group_label>MCLA-129</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors with evidence of metastatic or&#xD;
             locally advanced unresected disease that is incurable.&#xD;
&#xD;
          -  Patients with NSCLC or other solid tumors who have failed prior standard first-line&#xD;
             treatment. Patients must have progressed on or be intolerant to therapies that are&#xD;
             known to provide clinical benefit. There is no limit to the number of prior treatment&#xD;
             regimens.&#xD;
&#xD;
          -  Availability of archival or a fresh tumor tissue sample.&#xD;
&#xD;
          -  Measurable disease as defined by RECIST version 1.1 by radiologic methods.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks, as per Investigator.&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 X 109/L&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Platelets ≥100 x 109/L&#xD;
&#xD;
               -  Corrected total serum calcium within normal ranges&#xD;
&#xD;
               -  Serum magnesium within normal ranges (or corrected with supplements)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤3 x upper limit&#xD;
                  of normal (ULN) and total bilirubin ≤1.5 x ULN (patients with Gilbert's syndrome&#xD;
                  are eligible if conjugated bilirubin value is within normal limits); in cases of&#xD;
                  liver involvement, ALT/AST ≤5 x ULN and total bilirubin ≤2 x ULN will be allowed&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN or creatinine clearance ≥50 mL/min calculated&#xD;
                  according to the Cockcroft and Gault formula or MDRD formula for patients aged&#xD;
                  &gt;65 years&#xD;
&#xD;
               -  Serum albumin &gt;3.3 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system metastases that are untreated or symptomatic, or require&#xD;
             radiation, surgery, or continued steroid therapy (&gt; 10 mg prednisone or equivalent) to&#xD;
             control symptoms within 14 days of study entry.&#xD;
&#xD;
          -  Known leptomeningeal involvement.&#xD;
&#xD;
          -  Participation in another clinical study or treatment with any investigational drug&#xD;
             within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Prior treatment with a bispecific EGFR-c-MET antibody.&#xD;
&#xD;
          -  Systemic anticancer therapy or immunotherapy within 4 weeks or 5 half-lives, whichever&#xD;
             is shorter, of the first dose of study drug. For cytotoxic agents that have major&#xD;
             delayed toxicity (e.g., mitomycin C, nitrosoureas), a washout period of 6 weeks is&#xD;
             required.&#xD;
&#xD;
          -  Major surgery or radiotherapy within 3 weeks of the first dose of study drug.&#xD;
&#xD;
          -  Persistent grade &gt;1 clinically significant toxicities related to prior antineoplastic&#xD;
             therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v5.0&#xD;
             and hypothyroidism ≤ grade 2 which is stable on hormone replacement are allowed.&#xD;
&#xD;
          -  History of hypersensitivity reaction or any toxicity attributed to human proteins or&#xD;
             any of the excipients that warranted permanent cessation of these agents.&#xD;
&#xD;
          -  History of clinically significant cardiovascular disease including, but not limited&#xD;
             to:&#xD;
&#xD;
               -  Diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to&#xD;
                  first dose of study drug, or any of the following within 6 months prior to the&#xD;
                  first dose of study drug: myocardial infarction, unstable angina, stroke,&#xD;
                  transient ischemic attack, coronary/peripheral artery bypass graft, or any acute&#xD;
                  coronary syndrome.&#xD;
&#xD;
               -  Prolonged QT interval &gt; 480 msec or clinically significant cardiac arrythmia or&#xD;
                  electrophysiologic disease (i.e., placement of implantable cardioverter&#xD;
                  defibrillator or atrial fibrillation with uncontrolled rate). Patients with&#xD;
                  cardiac pacemakers who are clinically stable are eligible.&#xD;
&#xD;
               -  Uncontrolled (persistent) arterial hypertension: systolic blood pressure &gt; 180 mm&#xD;
                  Hg and/or diastolic blood pressure &gt; 100 mm Hg.&#xD;
&#xD;
               -  Congestive heart failure (CHF) defined as New York Heart Association (NYHA) class&#xD;
                  III-IV or hospitalization for CHF within 6 months of the first dose of study&#xD;
                  drug.&#xD;
&#xD;
               -  Clinically significant pericardial effusion.&#xD;
&#xD;
               -  Myocarditis.&#xD;
&#xD;
          -  History of interstitial lung disease including drug-induced interstitial lung disease,&#xD;
             radiation pneumonitis that requires treatment with prolonged steroids or other immune&#xD;
             suppressive agents within 1 year.&#xD;
&#xD;
          -  Previous or concurrent malignancy, excluding non-basal cell carcinomas of skin or&#xD;
             carcinoma in situ of the uterine cervix, unless the tumor was treated with curative or&#xD;
             palliative intent and in the opinion of the Investigator, with Sponsor agreement, the&#xD;
             previous or concurrent malignancy condition does not affect the assessment of safety&#xD;
             and efficacy of the study drug.&#xD;
&#xD;
          -  Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen&#xD;
             therapy.&#xD;
&#xD;
          -  Current serious illness or medical conditions including, but not limited to&#xD;
             uncontrolled active infection, clinically significant pulmonary, metabolic or&#xD;
             psychiatric disorders&#xD;
&#xD;
          -  Active Hepatitis B infection (HBsAg positive) without receiving antiviral treatment.&#xD;
&#xD;
          -  Positive test for Hepatitis C ribonucleic acid (HCV RNA);&#xD;
&#xD;
          -  Known history of HIV (HIV 1/2 antibodies).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Merus Inquiries</last_name>
    <phone>617-401-4499</phone>
    <email>USenquiries@merus.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>877-827-8839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Mountain Region</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-509-8520</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCLA-129</keyword>
  <keyword>EGFR inhibitor</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

